{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T13:08:03Z","timestamp":1693314483131},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T00:00:00Z","timestamp":1446076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T00:00:00Z","timestamp":1446076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/leu.2015.303","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T07:41:51Z","timestamp":1446104511000},"page":"1405-1409","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib"],"prefix":"10.1038","volume":"30","author":[{"given":"E A","family":"Lasater","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E S","family":"Massi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Stecula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Politi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S K","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C C","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Gunthorpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J P","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Chehab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Sali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N P","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,29]]},"reference":[{"key":"BFleu2015303_CR1","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374\u20137379.","journal-title":"Clin Cancer Res"},{"key":"BFleu2015303_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD . Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345\u2013356.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2015303_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938\u20131942.","journal-title":"Science"},{"key":"BFleu2015303_CR4","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66: 5790\u20135797.","journal-title":"Cancer Res"},{"key":"BFleu2015303_CR5","first-page":"4236","volume":"62","author":"B Nagar","year":"2002","unstructured":"Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236\u20134243.","journal-title":"Cancer Res"},{"key":"BFleu2015303_CR6","doi-asserted-by":"publisher","first-page":"e29828","DOI":"10.1371\/journal.pone.0029828","volume":"7","author":"NM Levinson","year":"2012","unstructured":"Levinson NM, Boxer SG . Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One 2012; 7: e29828.","journal-title":"PLoS One"},{"key":"BFleu2015303_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401\u2013412.","journal-title":"Cancer Cell"},{"key":"BFleu2015303_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014; 26: 428\u2013442.","journal-title":"Cancer Cell"},{"key":"BFleu2015303_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis MI, Hunt JP, Herrgard S, Ciceri Pietro, Wodicka LM, Pallares G et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1046\u20131051.","journal-title":"Nat Biotechnol"},{"key":"BFleu2015303_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature14119","volume":"519","author":"T Pemovska","year":"2015","unstructured":"Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 2015; 519: 102\u2013105.","journal-title":"Nature"},{"key":"BFleu2015303_CR11","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clini Invest 2007; 117: 2562\u20132569.","journal-title":"J Clini Invest"},{"key":"BFleu2015303_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876\u2013880.","journal-title":"Science"},{"key":"BFleu2015303_CR13","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/j.leukres.2011.08.011","volume":"36","author":"GF How","year":"2012","unstructured":"How GF, M\u00fcller MC, Lim LC . Acquistion of the novel ABL kinase domain mutation T315L in a relapsed Philadelphia-positive acute lymphoblastic leukemia patient. Leuk Res 2012; 36: e20\u2013e21.","journal-title":"Leuk Res"},{"key":"BFleu2015303_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/sj.thj.6200319","volume":"5","author":"H-K Al-Ali","year":"2004","unstructured":"Al-Ali H-K, Heinrich MC, Lange T, Krahl R, Mueller M, M\u00fcller C et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55\u201360.","journal-title":"Hematol J"},{"key":"BFleu2015303_CR15","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23338","volume":"87","author":"S Redaelli","year":"2012","unstructured":"Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M et al. Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 2012; 87: E125\u2013E128.","journal-title":"Am J Hematol"},{"key":"BFleu2015303_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","volume":"77","author":"T Zhou","year":"2011","unstructured":"Zhou T, Commodore L, Huang W-S, Wang Y, Thomas M, Keats J et al. Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011; 77: 1\u201311.","journal-title":"Chem Biol Drug Des"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015303","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:20:42Z","timestamp":1648743642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,29]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFleu2015303"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.303","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,29]]},"assertion":[{"value":"29 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}